Literature DB >> 25390976

Intravitreal bevacizumab (avastin) for radiation retinopathy 53 years after treatment of retinoblastoma.

Stephen J Kim1, G Baker Hubbard.   

Abstract

PURPOSE: To report the successful treatment of rubeosis and an atypical polypoidal vascular lesion in a case of radiation retinopathy treated with intravitreal bevacizumab.
METHODS: A 56-year-old woman with a history of retinoblastoma treated with radiation in the right eye was followed up for a progressively enlarging lesion in the macula that was associated with subretinal fluid. The patient was examined with serial ultrasound and clinical examinations and underwent pupilloplasty on the right eye to improve the view to her fundus. Fluorescein angiography revealed a vascular lesion with prominent saccular dilations. Her subsequent course was complicated by a retinal vein occlusion, rubeosis, and decreased vision.
RESULTS: A single treatment with intravitreal bevacizumab resulted in regression of the rubeosis and atypical polypoidal vascular lesion and subjective improvement in vision, which persisted for 3 months.
CONCLUSION: Rubeosis and atypical polypoidal neovascularization are known complications of radiation retinopathy, and treatment with intravitreal bevacizumab may be beneficial.

Entities:  

Year:  2007        PMID: 25390976     DOI: 10.1097/ICB.0b013e3180618c71

Source DB:  PubMed          Journal:  Retin Cases Brief Rep        ISSN: 1935-1089


  3 in total

1.  Central Serous Chorioretinopathy in a Case of Regressed Familial Retinoblastoma.

Authors:  Saeed Karimi; Amir Arabi; Toktam Shahraki; Sare Safi
Journal:  J Ophthalmic Vis Res       Date:  2020-10-25

2.  Short-term outcomes following treatment of recalcitrant cystoid macular edema secondary to radiation maculopathy using intravitreal brolucizumab.

Authors:  Giulia Corradetti; Federico Corvi; Alexander Juhn; SriniVas R Sadda
Journal:  Am J Ophthalmol Case Rep       Date:  2020-10-26

3.  Radiation Retinopathy 47 Years following Brachytherapy for Retinoblastoma.

Authors:  Claudine Bellerive; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2017-11-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.